GH Research PLC (GHRS)

NASD · Healthcare · Biotechnology · Ireland

GH Research PLC is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the GH Research PLC stock.

Our verdict on GHRS

Not valued: We cannot value this company yet.

ETFs with the most weight in GHRS

• Invesco Nasdaq Biotechnology ETF (IBBQ): 0.1% of the fund
• iShares Biotechnology ETF (IBB): 0.1% of the fund

Browse

• Stocks in Ireland
• Healthcare stocks in Ireland

Peers in Biotechnology

• Vertex Pharmaceuticals Inc (VRTX)
• Regeneron Pharmaceuticals Inc (REGN)
• Moderna Inc (MRNA)
• Argen X SE ADR (ARGX)
• Revolution Medicines Inc (RVMD)
• Royalty Pharma plc (RPRX)
• BeOne Medicines Ltd ADR (ONC)
• Genmab ADR (GMAB)

All 598 Biotechnology stocks

Cheaper than GHRS in Biotechnology

• Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
• Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 77% margin of safety
• CorMedix Inc (CRMD): undervalued, 74% margin of safety
• MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
• Bicycle Therapeutics Plc ADR (BCYC): undervalued, 71% margin of safety
• Innoviva Inc (INVA): undervalued, 71% margin of safety

134 more in this industry show a wider margin of safety.

Is GHRS undervalued or overvalued?

We do not publish a verdict on GHRS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of GHRS?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.